MENLO PARK, Calif., May 10, 2012 /PRNewswire/ --Depomed, Inc. (NASDAQ: DEPO) today announced that it will be presenting at the Bank of America Merrill Lynch Health Care Conference in Las Vegas, Nevada.
The presentation at the B of A conference is scheduled for 3:00 pm EDT (12 noon California time) on Wednesday, May 16, 2012. The presentation will be webcast, and the webcast can be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A recording of the webcast will be archived for 30 days on the company's website.
Depomed, Inc. is a specialty pharmaceutical company with two approved and marketed products. Gralise' (gabapentin) is a once-daily treatment approved for the management of postherpetic neuralgia (PHN). Glumetza® (metformin hydrochloride extended release tablets) is approved for use in adults with type 2 diabetes and is commercialized by Santarus, Inc. in the United States. Depomed formulates its products and product candidates with its proven, proprietary Acuform® drug delivery technology, which is designed to improve existing oral medications, allowing for extended release of medications to the upper gastrointestinal tract when dosed with food. Additional information about Depomed may be found on its website, www.depomed.com.
August J. Moretti
SOURCE Depomed, Inc.